LayerSlider
Targeting clinically-proven cancer biology
Expanding who will respond
to Immuno-Oncology therapies
Combining with other targeted therapies to
go beyond stopping progression and save lives
Selecting patients who will respond
Harnessing potent & selective candidates to
achieve new levels of efficacy
Leveraging an experienced drug development team